Literature DB >> 34346714

Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Thomas Garrigos1,2, Manon Dollat1, Arnaud Magallon1,2, Angélique Chapuis1, Véronique Varin1, Julien Bador1,2, Nadia Makki3, Lise Cremet4, Elise Persyn4, Emilie Cardot-Martin5, Fedoua Echahidi6, Charlotte Peeters7, Denis Pierard6, Peter Vandamme7, Alexia Verroken8, Catherine Neuwirth1,2, Lucie Amoureux1,2.   

Abstract

Achromobacter spp. are increasingly reported among cystic fibrosis patients. Genotyping requires time-consuming methods such as multilocus sequence typing or pulsed-field gel electrophoresis. Therefore, data on the prevalence of multiresistant epidemic clones, especially A. xylosoxidans ST137 (AxST137) and the Danish epidemic strain A. ruhlandii (DES), are lacking. We recently developed and published a database for Achromobacter species identification by matrix-assisted laser desorption-ionization-time of flight mass spectrometry (MALDI-TOF MS; Bruker Daltonics). The aim of this study was to evaluate the ability of the MALDI-TOF MS to distinguish these multiresistant epidemic clones within Achromobacter species. All the spectra of A. xylosoxidans (n = 1,571) and A. ruhlandii (n = 174) used to build the local database were analyzed by ClinProTools, MALDI Biotyper PCA, MALDI Biotyper dendrogram, and flexAnalysis software for biomarker peak detection. Two hundred two isolates (including 48 isolates of AxST137 and 7 of DES) were tested. Specific biomarker peaks were identified: absent peak at m/z 6,651 for AxST137 isolates and present peak at m/z 9,438 for DES isolates. All tested isolates were well typed by our local database and clustered within distinct groups (ST137 or non-ST137 and DES or non-DES) no matter the MALDI-TOF software or only by simple visual inspection of the spectra by any user. The use of MALDI-TOF MS allowed us to identify isolates of A. xylosoxidans belonging to the AxST137 clone that spread in France and Belgium (the Belgian epidemic clone) and of A. ruhlandii belonging to the DES clone. This tool will help the implementation of segregation measures to avoid interpatient transmission of these resistant clones.

Entities:  

Keywords:  Achromobacter ruhlandii; Achromobacter xylosoxidans; Danish epidemic strain; MALDI-TOF MS; ST137; cystic fibrosis; epidemic clones; typing

Mesh:

Year:  2021        PMID: 34346714      PMCID: PMC8451399          DOI: 10.1128/JCM.00946-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Identification of a proteomic biomarker associated with invasive ST1, serotype VI Group B Streptococcus by MALDI-TOF MS.

Authors:  Hsiao-Chuan Lin; Jang-Jih Lu; Lee-Chung Lin; Cheng-Mao Ho; Kao-Pin Hwang; Yu-Ching Liu; Chao-Jung Chen
Journal:  J Microbiol Immunol Infect       Date:  2017-12-30       Impact factor: 4.399

2.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the discrimination of food-borne microorganisms.

Authors:  Maria Fiorella Mazzeo; Alida Sorrentino; Marcello Gaita; Giuseppina Cacace; Michele Di Stasio; Angelo Facchiano; Giuseppe Comi; Antonio Malorni; Rosa Anna Siciliano
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

3.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry identifies Pseudomonas aeruginosa high-risk clones.

Authors:  Nadège Cabrolier; Marlène Sauget; Xavier Bertrand; Didier Hocquet
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

4.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry assigns Escherichia coli to the phylogroups A, B1, B2 and D.

Authors:  Marlène Sauget; Marie-Hélène Nicolas-Chanoine; Nadège Cabrolier; Xavier Bertrand; Didier Hocquet
Journal:  Int J Med Microbiol       Date:  2014-07-07       Impact factor: 3.473

5.  Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.

Authors:  Sabine Van Daele; Rita Verhelst; Geert Claeys; Gerda Verschraegen; Hilde Franckx; Leen Van Simaey; Catharine de Ganck; Frans De Baets; Mario Vaneechoutte
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Rapid identification of protein biomarkers of Escherichia coli O157:H7 by matrix-assisted laser desorption ionization-time-of-flight-time-of-flight mass spectrometry and top-down proteomics.

Authors:  Clifton K Fagerquist; Brandon R Garbus; William G Miller; Katherine E Williams; Emma Yee; Anna H Bates; Síobhán Boyle; Leslie A Harden; Michael B Cooley; Robert E Mandrell
Journal:  Anal Chem       Date:  2010-04-01       Impact factor: 6.986

7.  Diversity of Achromobacter species recovered from patients with cystic fibrosis, in Argentina.

Authors:  Mariana Papalia; Carla Steffanowski; Germán Traglia; Marisa Almuzara; Pablo Martina; Laura Galanternik; Carlos Vay; Gabriel Gutkind; María Soledad Ramírez; Marcela Radice
Journal:  Rev Argent Microbiol       Date:  2019-06-26       Impact factor: 1.852

8.  Evaluation of MALDI-TOF mass spectroscopy methods for determination of Escherichia coli pathotypes.

Authors:  Clifford G Clark; Peter Kruczkiewicz; Cai Guan; Stuart J McCorrister; Patrick Chong; John Wylie; Paul van Caeseele; Helen A Tabor; Phillip Snarr; Matthew W Gilmour; Eduardo N Taboada; Garrett R Westmacott
Journal:  J Microbiol Methods       Date:  2013-06-28       Impact factor: 2.363

9.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

10.  Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.

Authors:  R H V Pereira; R S Leão; A P Carvalho-Assef; R M Albano; E R A Rodrigues; M C Firmida; T W Folescu; M C Plotkowski; V G Bernardo; E A Marques
Journal:  Epidemiol Infect       Date:  2016-11-22       Impact factor: 4.434

View more
  2 in total

1.  Distribution of Achromobacter Species in 12 French Cystic Fibrosis Centers in 2020 by a Retrospective MALDI-TOF MS Spectrum Analysis.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Anaïs Folletet; Julien Bador; Maryam Abid; Marlène Amara; Clémence Beauruelle; Olivier Belmonte; Pierre Boyer; Emilie Cardot-Martin; Anne-Gaëlle Cauchie; Sylvie Colin de Verdière; Claire Daurel; Cécile Gaudru; Farida Hamdad; Geneviève Héry-Arnaud; Baptiste Hoellinger; Claudie Lamoureux; Marie-Frédérique Lartigue; Damasie Malandain; Océane Marchand; Caroline Piau; Sandrine Picot; Hélène Revillet; Zeina Sabouni; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2022-05-05       Impact factor: 11.677

2.  An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics of Achromobacter spp. (Labeled Biochemically or by MAL-DI-TOF MS as A. xylosoxidans), Largely in Patient Groups Other than Those with CF.

Authors:  Claudio Neidhöfer; Christina Berens; Marijo Parčina
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.